Health
Kratom-derived compound faces regulatory scrutiny over opioid effects and retail availability
The Hill reports that retail sales of 7-OH persist despite federal recommendations to classify it as a Schedule I substance.
The short version
- The compound 7-OH, produced by chemically oxidizing kratom extract, is being sold legally in convenience stores.[The Hill]
- Federal health officials classify 7-OH as an opioid, citing studies showing it binds to mu-opioid receptors up to 13 times more potently than morphine.[The Hill]
- The FDA recommended scheduling 7-OH as a Schedule I drug in July 2025, while several states have already introduced bans or emergency rules.[The Hill]
- Disputes continue over its classification, as some individuals maintain that the substance is not an opioid.[The Hill]
Key facts
- 7-OH is manufactured by chemically oxidizing extract from kratom.[The Hill]
- Research indicates 7-OH binds to mu-opioid receptors with potency reported up to 13 times higher than morphine.[The Hill]
- The FDA recommended on July 29, 2025, that 7-OH be designated a Schedule I controlled substance.[The Hill]
- States including Florida, Tennessee, Massachusetts, Kansas, and North Dakota have enacted emergency rules or bans restricting 7-OH.[The Hill]
What remains uncertain
- While the FDA and HHS classify 7-OH as an opioid, some individuals dispute whether the compound should be categorized as such.[The Hill]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.